We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarker Evaluated for Early Detection of Congenital Heart Disease

By LabMedica International staff writers
Posted on 16 Dec 2020
Print article
Image: The GSP instrument is a high throughput batch analyzer intended for quantitative or qualitative measurement of neonatal screening samples on 96-well microplates (Photo courtesy of PerkinElmer).
Image: The GSP instrument is a high throughput batch analyzer intended for quantitative or qualitative measurement of neonatal screening samples on 96-well microplates (Photo courtesy of PerkinElmer).
Congenital heart disease (CHD) is the most common congenital malformation in humans worldwide. Circulating cardiovascular biomarkers could potentially improve the early detection of CHD, even in asymptomatic newborns.

The amino terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) test has been used in adults with cardiac failure. Evidence has found that the NT-proBNP test is useful in infants who require neonatal intensive care, children with pulmonary hypertension and cardiomyopathies, and children with various types of CHD.

Pediatricians at the University Teaching Hospital Ryhov (Jönköping, Sweden) and their colleagues prospectively enrolled healthy, term neonates born between July 1, 2018, and May 31, 2019 and compared them against retrospectively identified newborns with CHD born between September 1, 2003, and September 30, 2019. The CHD diagnosis was confirmed by echocardiography. Control newborns were followed-up for a minimum of one year using electronic patient records covering routine checkups and additional medical consultations.

The scientists developed a fully automated immunoassay for NT-proBNP measurement from dried blood spot (DBS) samples. Microtitration strips 96-well format were coated with anti-NT-proBNP mouse monoclonal IgG antibody (HyTest Ltd, Turku, Finland) and the monoclonal tracer antibody (HyTest Ltd) was labeled with europium chelate. The hematocrit in this mix was checked with a Coulter Ac · T diff Hematology Analyzer (Beckman Coulter, Brea, CA, USA). A high throughput batch analyzer (GSP Instrument; PerkinElmer, Waltham, MA, USA) was used for the plate assays.

Performed as early as two days after birth, a dried blood spot (DBS) test for NT-proBNP flagged 71% of the 34 tested babies with known CHD and 68% of the critical CHD cases. Combining the DBS test with pulse oximetry screening improved CHD detection to 82% and detection of critical CHD to 89%. Babies with CHD had a median NT-proBNP level of 17,240 ng/L based on the DBS test. Healthy controls had significantly lower NT-proBNP levels, with a median of 1,900 ng/L. A comparison of DBS and standard screening for NT-proBNP (laboratory analysis on 500 μL of blood in a collection tube containing EDTA as an anticoagulant) found the two tests to be highly correlated and in good agreement.

The authors concluded that the DBS NT-proBNP test discriminated well between healthy newborns and newborns with various types of CHD, including critical lesions. Additional reference values were established for days two to four of life, reflecting the timing of common newborn screening programs. The study was published on December 2, 2020 in the journal JAMA Network Open.

Related Links:
University Teaching Hospital Ryhov
HyTest Ltd
Beckman Coulter
PerkinElmer


Gold Supplier
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
New
Silver Supplier
Remote Lab Review Software
CellaVision Remote Review Software
New
COVID-19 Portable Test Kit
VersaLab Portable
New
SARS-CoV-2 Nucleoprotein IgG Antibody ELISA Kit
SARS-CoV-2 Nucleoprotein IgG Antibody ELISA Kit

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.